Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Opioid Receptors Revealed

Structural Biology: Teams unveil structures of membrane proteins involved in pain, pleasure signaling

by Lauren K. Wolf
March 26, 2012 | A version of this story appeared in Volume 90, Issue 13

[+]Enlarge
Credit: Nature
As shown in this cutaway view, the inhibitor JDTic fits snugly into the large binding pocket of the κ-opioid receptor.
As shown in this cutaway view, the binding pocket of the kappa-opioid receptor is large and deep, thus able to accommodate a number of compounds, including the experimental drug JDTic (shown) (it has indications for treating anxiety and depression).
Credit: Nature
As shown in this cutaway view, the inhibitor JDTic fits snugly into the large binding pocket of the κ-opioid receptor.

A friendly competition to determine the structures of membrane proteins that mediate pain and pleasure has drawn to a close. Last week, Nature published two research teams’ X-ray crystal structures of the µ- and κ-opioid receptors, members of the G protein-coupled receptor (GPCR) family that bind drugs such as morphine and the hallucinogen salvinorin A (DOI: 10.1038/nature10954 and 10.1038/nature10939).

GPCRs are targets for approximately 40% of clinically approved drugs, so their structures are at the top of many drug companies’ wish lists. In particular, the µ- and κ-opioid receptor structures could aid in the design of new painkillers and antidepressants that have few side effects. No opioid receptor structures had previously been solved.

Neither team knew that the other had solved its opioid receptor structure until both attended a GPCR workshop held last December in Hawaii. After each group announced its results, “the race was on” to publish, says Bryan L. Roth, a member of the κ-opioid receptor team and a pharmacologist at the University of North Carolina, Chapel Hill.

Raymond C. Stevens of Scripps Research Institute led the κ receptor team, which determined the structure of the human κ receptor complexed with the inhibitor JDTic, a drug candidate for treating addiction.

[+]Enlarge
Credit: The Kobilka Lab
Two μ-opioid receptors dimerize (blue and purple), according to an X-ray crystal structure. The yellow compound is the inhibitor β-funaltrexamine.
The X-ray crystal structure of the mu-opioid receptor revealed that the protein forms dimers with itself (blue and purple) a phenomenon that could have implications for its function. Yellow structure inside is a drug derived from morphine.
Credit: The Kobilka Lab
Two μ-opioid receptors dimerize (blue and purple), according to an X-ray crystal structure. The yellow compound is the inhibitor β-funaltrexamine.

Stevens’ team found that, compared with previously solved GPCR structures, the κ receptor has an exceptionally large binding pocket. On the basis of previous modeling and mutagenesis studies, Roth says, “it was never clear why κ could bind so many different types of compounds. Now it’s very clear.” The pocket fits many molecules, he explains, and their binding strength depends upon which of the pocket’s amino acid residues they interact with.

The µ receptor team, led by Brian K. Kobilka and Sébastien Granier of Stanford University’s School of Medicine, also found that its membrane protein has a big, exposed binding pocket. The researchers solved the structure of a mouse µ-opioid receptor bound to the inhibitor β-funaltrexamine, a morphinelike compound.

Both teams found that their receptors dimerized. Pairs of µ receptors have especially large surface areas, Kobilka says. It’s not clear at this point what the significance of this dimerization might be or whether it occurs in cell membranes, he adds, but “the structure will help design experiments to test the functional role of this interface.”

Although the two teams have yet to closely compare structural data, this is where the real excitement will be, says Christopher G. Tate, a structural biologist at MRC Laboratory of Molecular Biology, in England. “Comparing in minute detail how the two receptors bind their respective inhibitors,” he adds, “should help in making drugs that bind specifically to only one receptor in the opioid receptor family.”

Advertisement

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.